Traditional medical care will likely look very different in the post-pandemic world. Routine medical care and even surgery and childbirth may be performed in an office or home setting, as patients seek to reduce exposure to COVID-19 and other infectious agents. As more technology necessary for medical care beomes accessbile and mobile, the treatment platforms will transition to less centralized care.
A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen consisting of the antiviral remdesivir plus the immunomodulator interferon beta-1a in patients with coronavirus disease 2019 (COVID-19) has begun. The study, called the Adaptive COVID-19 Treatment Trial 3 (ACTT 3), is anticipated to enroll more than 1,000 hospitalized adults with COVID-19 at as many as 100 sites in the United States and abroad.
In a comparative analysis published late last week in Clinical Infectious Diseases, the antiviral drug remdesivir was linked to significantly greater recovery and a 62% lower death rate by day 14 versus standard treatment in hospitalized adults with severe COVID-19. Researchers used data from 298 participants in an ongoing phase 3 trial of remdesivir at 45 international sites, as well as retrospective data from an ongoing real-world longitudinal study of 816 patients given standard treatment at 16 international sites.
Research out of Boston University shows "Nanosponges" could act as a decoy and prevent the SARS-CoV-2 virus from taking hold of lung cells. This Research was supported by the Defense Threat Reduction Agency Joint Science and Technology office for Chemical and Biological Defense.
A recent study found 30% of all published papers since January 2020 on COVID-19 were authored by women. This study suggests gender biases seem to be affecting COVID-19 research similar to other scientific areas, highlighting that women are consistently being under-represented.
A recent study in Nature found shutdown orders prevented 60 million COVID-19 infections in the United States and 285 million COVID-19 infections in China.
This study analyzed the transmission of coronavirus disease outside of the Daegu-Gyeongsangbuk provincial region in South Korea. The study estimated that nonpharmaceutical measures reduced transmissibility by a maximum of 34% without resorting to a strict lockdown strategy.
The World Health Organization reported the cumulative case-count of confirmed COVID-19 in the WHO African Region has topped 100 000 as the pandemic continues to grow. The trajectory of the pandemic in the region is on the rise, both in terms of case incidence and mortality. Meanwhile, many countries in the region are now easing confinement measures introduced to control the spread of the virus.
The Pan American Health Organization (PAHO) recently reported 250,000 of the world's 732,000 COVID-19 cases were in Latin America.
A new Canadian Government study showed a 59.1% increase in MRSA bloodstream infections (0.66 to 1.05 infections per 10,000 patient-days) and a 143% increase in VRE bloodstream infections (0.14 to 0.34 infections per 10,000 patient-days).